162 related articles for article (PubMed ID: 16243476)
1. Changing patterns of fluoroquinolone resistance among Bacteroides fragilis group organisms over a 6-year period (1997-2002).
Betriu C; Rodríguez-Avial I; Gómez M; Culebras E; Picazo JJ
Diagn Microbiol Infect Dis; 2005 Nov; 53(3):221-3. PubMed ID: 16243476
[TBL] [Abstract][Full Text] [Related]
2. In vitro activities of newer quinolones against bacteroides group organisms.
Snydman DR; Jacobus NV; McDermott LA; Ruthazer R; Goldstein E; Finegold S; Harrell L; Hecht DW; Jenkins S; Pierson C; Venezia R; Rihs J; Gorbach SL
Antimicrob Agents Chemother; 2002 Oct; 46(10):3276-9. PubMed ID: 12234859
[TBL] [Abstract][Full Text] [Related]
3. Activities of new antimicrobial agents (trovafloxacin, moxifloxacin, sanfetrinem, and quinupristin-dalfopristin) against Bacteroides fragilis group: comparison with the activities of 14 other agents.
Betriu C; Gómez M; Palau ML; Sánchez A; Picazo JJ
Antimicrob Agents Chemother; 1999 Sep; 43(9):2320-2. PubMed ID: 10471590
[TBL] [Abstract][Full Text] [Related]
4. Gatifloxacin, gemifloxacin, and moxifloxacin: the role of 3 newer fluoroquinolones.
Saravolatz LD; Leggett J
Clin Infect Dis; 2003 Nov; 37(9):1210-5. PubMed ID: 14557966
[TBL] [Abstract][Full Text] [Related]
5. Lessons learned from the anaerobe survey: historical perspective and review of the most recent data (2005-2007).
Snydman DR; Jacobus NV; McDermott LA; Golan Y; Hecht DW; Goldstein EJ; Harrell L; Jenkins S; Newton D; Pierson C; Rihs JD; Yu VL; Venezia R; Finegold SM; Rosenblatt JE; Gorbach SL
Clin Infect Dis; 2010 Jan; 50 Suppl 1():S26-33. PubMed ID: 20067390
[TBL] [Abstract][Full Text] [Related]
6. Emergence of fluoroquinolone resistance among Bacteroides species.
Golan Y; McDermott LA; Jacobus NV; Goldstein EJ; Finegold S; Harrell LJ; Hecht DW; Jenkins SG; Pierson C; Venezia R; Rihs J; Iannini P; Gorbach SL; Snydman DR
J Antimicrob Chemother; 2003 Aug; 52(2):208-13. PubMed ID: 12865399
[TBL] [Abstract][Full Text] [Related]
7. National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.
Snydman DR; Jacobus NV; McDermott LA; Ruthazer R; Golan Y; Goldstein EJ; Finegold SM; Harrell LJ; Hecht DW; Jenkins SG; Pierson C; Venezia R; Yu V; Rihs J; Gorbach SL
Antimicrob Agents Chemother; 2007 May; 51(5):1649-55. PubMed ID: 17283189
[TBL] [Abstract][Full Text] [Related]
8. In vitro activity of moxifloxacin against 923 anaerobes isolated from human intra-abdominal infections.
Goldstein EJ; Citron DM; Warren YA; Tyrrell KL; Merriam CV; Fernandez H
Antimicrob Agents Chemother; 2006 Jan; 50(1):148-55. PubMed ID: 16377680
[TBL] [Abstract][Full Text] [Related]
9. In vitro activity of trovafloxacin against Bacteroides fragilis in mixed culture with either Escherichia coli or a vancomycin- resistant strain of Enterococcus faecium determined by an anaerobic time-kill technique.
Stearne LE; Kooi C; Goessens WH; Bakker-Woudenberg IA; Gyssens IC
Antimicrob Agents Chemother; 2001 Jan; 45(1):243-51. PubMed ID: 11120973
[TBL] [Abstract][Full Text] [Related]
10. gyrA mutations associated with quinolone resistance in Bacteroides fragilis group strains.
Oh H; El Amin N; Davies T; Appelbaum PC; Edlund C
Antimicrob Agents Chemother; 2001 Jul; 45(7):1977-81. PubMed ID: 11408211
[TBL] [Abstract][Full Text] [Related]
11. Emergence of high-level fluoroquinolone resistance in emm6 Streptococcus pyogenes and in vitro resistance selection with ciprofloxacin, levofloxacin and moxifloxacin.
Malhotra-Kumar S; Van Heirstraeten L; Lammens C; Chapelle S; Goossens H
J Antimicrob Chemother; 2009 May; 63(5):886-94. PubMed ID: 19279051
[TBL] [Abstract][Full Text] [Related]
12. Intra-abdominal anaerobic infections: bacteriology and therapeutic potential of newer antimicrobial carbapenem, fluoroquinolone, and desfluoroquinolone therapeutic agents.
Goldstein EJ
Clin Infect Dis; 2002 Sep; 35(Suppl 1):S106-11. PubMed ID: 12173118
[TBL] [Abstract][Full Text] [Related]
13. Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
Lee Y; Park Y; Kim MS; Yong D; Jeong SH; Lee K; Chong Y
Antimicrob Agents Chemother; 2010 Sep; 54(9):3993-7. PubMed ID: 20585132
[TBL] [Abstract][Full Text] [Related]
14. [Activity of trovafloxacin and ten other antimicrobials against gram negative anaerobic bacilli].
Chávez M; García López JL; Coronilla J; Bernal S; Valverde A; Martín Mazuelos E
Rev Esp Quimioter; 1998 Dec; 11(4):349-52. PubMed ID: 9990149
[TBL] [Abstract][Full Text] [Related]
15. Urinary concentrations and bactericidal activities of newer fluoroquinolones in healthy volunteers.
Stein GE; Schooley S
Int J Antimicrob Agents; 2004 Aug; 24(2):168-72. PubMed ID: 15288316
[TBL] [Abstract][Full Text] [Related]
16. [Evolution of the sensitivity of Bacteroides group fragilis at the Sevilla University Hospital (1983-1987)].
Borobio MV; Domínguez MC; Pallares JA; Perea EJ
Enferm Infecc Microbiol Clin; 1991 Apr; 9(4):214-8. PubMed ID: 1863620
[TBL] [Abstract][Full Text] [Related]
17. Moxifloxacin resistance is prevalent among Bacteroides and Prevotella species in Greece.
Papaparaskevas J; Pantazatou A; Katsandri A; Houhoula DP; Legakis NJ; Tsakris A; Avlamis A
J Antimicrob Chemother; 2008 Jul; 62(1):137-41. PubMed ID: 18385145
[TBL] [Abstract][Full Text] [Related]
18. Effect of recombinant murine granulocyte colony-stimulating factor with or without fluoroquinolone therapy on mixed-infection abscesses in mice.
Stearne LE; Vonk AG; Kullberg BJ; Gyssens IC
Antimicrob Agents Chemother; 2005 Sep; 49(9):3668-75. PubMed ID: 16127038
[TBL] [Abstract][Full Text] [Related]
19. Susceptibility trends of Bacteroides fragilis group isolates from Buenos Aires, Argentina.
Fernández Canigia L; Castello L; Di Martino A; Greco G; Legaria MC; Litterio M; Predari SC; Rollet R; Rossetti A; Carloni G; Sarchi MI; Bianchini H
Rev Argent Microbiol; 2007; 39(3):156-60. PubMed ID: 17987852
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the efficacy and safety of moxifloxacin and trovafloxacin for the treatment of acute, bacterial maxillary sinusitis in adults.
Klossek JM; Siegert R; Nikolaidis P; Arvis P; Leberre MA;
J Laryngol Otol; 2003 Jan; 117(1):43-51. PubMed ID: 12590855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
